Kaye David M, Krum Henry
Wynn Department of Metabolic Cardiology, Baker Heart Research Institute, PO Box 6492, St Kilda Road Central, Victoria 8008, Australia.
Nat Rev Drug Discov. 2007 Feb;6(2):127-39. doi: 10.1038/nrd2219.
Although there have been significant advances in the therapy of heart failure in recent decades, such as the introduction of beta-blockers and antagonists of the renin-angiotensin system, there is still a major unmet need for better therapies for many patients with heart failure. However, disappointment related to late-stage clinical failures of a number of novel agents, including endothelin antagonists and tumour-necrosis factor blockers, has reduced the impetus of drug development in this field. Here, we review possible targets for heart failure therapy that have emerged from recent progress in our understanding of the underlying disease mechanisms, and highlight key issues that need to be addressed to improve the chances of success of novel therapies directed against these targets.
尽管近几十年来心力衰竭的治疗取得了重大进展，如引入了β受体阻滞剂和肾素-血管紧张素系统拮抗剂，但对于许多心力衰竭患者而言，仍亟需更好的治疗方法。然而，包括内皮素拮抗剂和肿瘤坏死因子阻滞剂在内的多种新型药物在后期临床试验中失败，令人失望，这降低了该领域药物研发的动力。在此，我们回顾了基于对潜在疾病机制的最新认识而出现的心力衰竭治疗可能的靶点，并强调了为提高针对这些靶点的新型治疗方法的成功率而需要解决的关键问题。
